104 related articles for article (PubMed ID: 25572590)
21. Preliminary study on XAGE-1b gene and its mechanism for promoting tumor cell growth.
Zhou B; Li T; Liu Y; Zhu N
Biomed Rep; 2013 Jul; 1(4):567-572. PubMed ID: 24648988
[TBL] [Abstract][Full Text] [Related]
22. NLS-dependent and insufficient nuclear localization of XAGE-1 splice variants.
Zhao R; Tang B; Liu Y; Zhu N
Oncol Rep; 2011 Apr; 25(4):1083-9. PubMed ID: 21305256
[TBL] [Abstract][Full Text] [Related]
23. XAGE-1 mRNA expression in prostate cancer and antibody response in patients.
Koizumi F; Noguchi Y; Saika T; Nakagawa K; Sato S; Eldib AM; Nasu Y; Kumon H; Nakayama E
Microbiol Immunol; 2005; 49(5):471-6. PubMed ID: 15905609
[TBL] [Abstract][Full Text] [Related]
24. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.
Kikuchi E; Yamazaki K; Nakayama E; Sato S; Uenaka A; Yamada N; Oizumi S; Dosaka-Akita H; Nishimura M
Cancer Immun; 2008 Aug; 8():13. PubMed ID: 18752338
[TBL] [Abstract][Full Text] [Related]
25. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
26. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
[TBL] [Abstract][Full Text] [Related]
27. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
Tan G; Wang ZY; Yin S
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
[TBL] [Abstract][Full Text] [Related]
29. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.
Chiriva-Internati M; Yu Y; Mirandola L; D'Cunha N; Hardwicke F; Cannon MJ; Cobos E; Kast WM
Prostate; 2012 Jan; 72(1):12-23. PubMed ID: 21520158
[TBL] [Abstract][Full Text] [Related]
30. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
31. [Association of XAGE-1 gene expression with clinical characteristics of lung cancer].
Lai Q; Zhang L; Sun Y
Zhongguo Fei Ai Za Zhi; 2010 Aug; 13(8):786-9. PubMed ID: 20704819
[TBL] [Abstract][Full Text] [Related]
32. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
[TBL] [Abstract][Full Text] [Related]
33. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
34. [Construction of eukaryotic expression vector of mouse alpha-fetoprotein cDNA and its expression in dendritic cells and in vitro antitumor effect on hepatoma].
Zeng B; Lu FG; Liu XW; Yang DY; Fang WY; Wang J; Liao AJ; Shi W
Ai Zheng; 2005 Nov; 24(11):1332-7. PubMed ID: 16552958
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
36. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
37. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
38. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
39. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
40. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
